Advanced Inhalation Therapies (AIT), which is developing inhaled nitric oxide drug-device therapies for respiratory infections, reported financial results for the six months ended August 1, 2015 in an amendment filed with the SEC on Thursday. The Rehovot, Israel-based company originally filed in August 2015 for an IPO to raise $36 million.
Advanced Inhalation Therapies (AIT), which was founded in 2011, plans to list on the Nasdaq under the symbol AITP. Aegis Capital Corp. is the sole bookrunner on the deal.